Online inquiry

IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2543MR)

This product GTTS-WQ2543MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2543MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6315MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ1812MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ1045MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ12401MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ4274MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB-033
GTTS-WQ12800MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ13248MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ12529MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NPVPDR001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW